Risk of breast cancer and family history of other cancers in first-degree relatives in Chinese women: a case control study by Wenbin Zhou et al.
Zhou et al. BMC Cancer 2014, 14:662
http://www.biomedcentral.com/1471-2407/14/662RESEARCH ARTICLE Open AccessRisk of breast cancer and family history of other
cancers in first-degree relatives in Chinese
women: a case control study
Wenbin Zhou†, Qiang Ding†, Hong Pan†, Naping Wu, Mengdi Liang, Yaoyu Huang, Lin Chen, Xiaoming Zha,
Xiaoan Liu* and Shui Wang*Abstract
Background: Few studies have systematically reported the relationship between the risk of breast cancer and
family history of other cancers. This study was designed to systematically determine the relationship between
breast cancer risk and family history of other cancers in first-degree relatives.
Methods: Between January 2006 and June 2011, 823 women diagnosed with breast cancer were included, and
age-matched women diagnosed with benign breast disease were selected as controls. Family history of other
cancers in first-degree relatives was recorded by trained reviewers. Multivariate logistic regression was applied to
analyze the relationships.
Results: A family history of esophagus cancer (OR: 2.70, 95% CI: 1.11 – 6.57), lung cancer (OR: 2.49 95% CI: 1.10 – 5.65),
digestive system cancer (OR: 1.79, 95% CI: 1.14 – 2.79) and any cancer (OR: 2.13, 95% CI: 1.49 – 3.04) in first-degree
relatives was directly associated with increased breast cancer risk. In subgroup analysis, the risk of hormone receptor
positive breast cancer was increased in subjects with a family history of lung cancer (OR: 3.37, 95% CI: 1.45 – 7.82), while
the risk of hormone receptor negative breast cancer was increased in subjects with a family history of esophagus
cancer (OR: 6.19, 95% CI: 2.30 – 16.71), uterus cancer (OR: 6.92, 95% CI: 1.12 – 42.89), digestive tract cancer
(OR: 2.05, 95% CI: 1.03 – 4.10) and gynecology cancer (OR: 6.79, 95% CI: 1.46 – 31.65). Additionally, a significant increase
in breast cancer was observed with a family history of digestive system cancer for subjects 50 y and younger (OR: 1.88,
95% CI: 1.03 – 3.43), not for subjects 50 y older (OR: 1.67, 95% CI: 0.86 – 3.25).
Conclusions: Breast cancer aggregates in families with several types of cancer especially for digestive system cancer.
The influence of a family history of other cancers seems more likely to be limited to hormone receptor negative
breast cancer.
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Breast cancer is a prevalent malignant disease in the world
and the leading cause of death in women [1,2]. Plentiful
risk factors have been identified, including anthropometric
factors, reproductive factors, home environment, and gen-
etic factors [3-5]. Family history of breast cancer is a key
breast cancer risk factor. It provides clues as to the like-
lihood of a hereditary breast cancer syndrome and the* Correspondence: liuxiaoan@126.com; ws0801@hotmail.com
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unless otherwise stated.need for cancer genetics, and can be used to estimate a
woman’s risk in the setting of a breast cancer risk as-
sessment model [6,7].
Importantly, several studies have suggested that an in-
creased breast cancer risk is observed in subjects with a
family history of other cancers, including colon cancer,
prostate cancer, ovarian cancer and some other cancers
[8-11]. To our knowledge, few studies have systematically
reported the relationship between the risk of breast cancer
and family history of other cancers. Negri E and colleagues
have found there was no material association between
family history of cancer (breast cancer excluding) andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Zhou et al. BMC Cancer 2014, 14:662 Page 2 of 7
http://www.biomedcentral.com/1471-2407/14/662breast cancer risk in Italy [8]. The magnitude of the asso-
ciation with family history varies between studies, cancer
sites, countries, and state of sex and age, being generally
stronger for younger probands [3,12-15]. Thus, it is neces-
sary and important to determine the relationship between
family history of all cancers and the risk of breast cancer
in different populations.
According to estrogen receptor (ER) and progesterone
receptor (PR) status, breast cancer can be divided into
two subgroups: hormone receptor positive and negative
breast cancer. Hormone receptor positive and negative
breast cancer may share disparate genetic risk factor
profiles [16-19]. To our knowledge, the relationship be-
tween having a family history of other cancers and risk of
subtype of breast cancer has not been reported. Addition-
ally, previous studies have reported that patients (colorec-
tal and lung cancer) with a family history of cancer were
younger than those without a family history [20,21]. In
our country, about 40% of breast cancer patients are
younger than 50 years old [22-24]. Therefore, it is import-
ant to determine the relationship between family history
of other cancers and breast cancer risk among women
younger than 50 years old.
Given poor reliability of the recall of cancer in second-
degree relatives [8], only first-degree relatives were used
in our analysis to reduce recall bias. This hospital-based
case-control study was designed to systematically deter-
mine the relationship between breast cancer risk and
family history of other cancers in first-degree relatives.
In addition, the relationship between family history of
other cancers and breast cancer risk among women
younger and older than 50 years old was determined.
Also, the relationship between family history of other
cancers and hormone receptor positive or negative
breast cancer risk was investigated separately.
Methods
Study population
As previously described [25], eligible women were aged
23 – 83 years, with histological confirmed breast cancer
between January 2006 and June 2011 in our hospital,
and 1:1 age-matched (±5 years) controls were selected in
the same period, with histological confirmed benign
breast disease, including fibroadenoma (316), mastopathy
(97), intraductal papilloma (311), and others (99). Of these
823 controls, 311 (intraductal papilloma) were classified
as benign breast disease with a low risk of developing
breast cancer, and only 13 (atypical hyperplasia) were clas-
sified as benign breast disease with a high risk of develop-
ing breast cancer [26].
The present case-control study was performed with
the approval of the ethics committee of The First Affiliated
Hospital with Nanjing Medical University, and this study
was also in compliance with the Helsinki Declaration ofthe World Medical Association. All patients included in
this study provided written informed consent for their
clinical data to be reviewed by us.
Data extraction
The interviews of family history for all cases and controls
were performed before diagnose. The clinical data were
reviewed by trained interviewers. The family history of
other cancers and potential risk factors were extracted
from medical record review. As described previously [25],
the following potential risk factors were collected: age, age
at menarche, previous childbearing, menopausal status.
Family history of cancers was not complete in 60 cases
and 9 controls. Otherwise, age at menarche was not avail-
able in 219 cases and 154 controls; previous childbearing
was not available in 144 cases and 77 controls; meno-
pausal status was not available in 105 cases and 41
controls.
Besides, ER and PR status were reviewed and recorded.
Immunohistochemical analyses on paraffin-embedded
material were used to determine the ER and PR status.
The cut-off positivity was 10% tumor cells for the evalu-
ation of ER and PR. Hormone receptor positive was de-
fined as ER positive and/or PR positive, and hormone
receptor negative was defined as both ER and PR were
negative. Of 823 cases, 514 were identified as hormone
receptor positive, 214 were identified as hormone recep-
tor negative, and hormone receptor status could not be
identified in 95 cases.
Statistical analysis
Median, percentiles, range, and standard deviation (SD)
were analyzed for each continuous variable. Univariate
and multivariate analyses were applied to estimate odds
ratio (OR) and 95% confidence interval (CI) for the as-
sociation between family history of other cancers and
breast cancer risk. In addition, multivariate logistic re-
gression was also applied to estimate OR and 95%CI for
the association between family history of other cancers
and risk of subtype-specific breast cancer, including
hormone receptor positive breast cancer, hormone re-
ceptor negative breast cancer, patients diagnosed with
breast cancer ≤ 50 years, and patients diagnosed with
breast cancer > 50 years. The candidate explanatory vari-
ables in the multivariate logistic regression analysis were:
age (≤30, 31-40, 41-50, 51-60, 61-70, 71-80, and ≥ 81 years),
age at menarche (≤13, 14-16, and ≥17 years), previous
childbearing (0, 1, 2, and ≥3) and menopausal status
(premenopause, and postmenopause). The categories of
age, age at menarche, and previous childbearing were
described previously [25]. All variables in the multivari-
ate logistic regression analyses were defined as grouping
variables, not continuous variables. All statistical analyses
were performed by using Stata version 11.0 (StataCorp,
Table 2 Odds ratio of breast cancer according to family






Breast 26/16 1.76 (0.94 – 3.31)) 2.32 (1.07 – 5.03)
Lung 21/13 1.74 (0.87 – 3.51) 2.49 (1.10 – 5.65)
Esophagus 18/7 2.79 (1.16 – 6.71) 2.70 (1.11 – 6.57)
Stomach 19/17 1.20 (0.62 – 2.32) 1.27 (0.61 – 2.61)
Intestine 7/8 0.93 (0.34 – 2.59) 0.91 (0.29 – 2.80)
Liver 10/5 2.15 (0.73 – 6.32) 2.25 (0.75 – 6.73)
Pancreas 6/5 1.28 (0.39 – 4.22) 1.44 (0.43 – 4.84)
Gallbladder 1/2 0.53 (0.05 – 5.89) 1.25 (0.08 – 20.36)
Larynx 5/2 2.68 (0.52 – 13.84) 4.41 (0.49 – 39.98)
Bladder 1/5 0.21 (0.02 – 1.82) 0.27 (0.03 – 2.44)
Kidney 2/1 2.14 (0.19 – 23.61) 2.08 (0.19 – 23.37)
Prostate 1/2 0.53 (0.05 – 5.89) 1.94 (0.12 – 32.42)
Uterus 7/3 2.50 (0.64 – 9.71) 3.84 (0.79 – 18.73)
Appendix 2/2 1.07 (0.15 – 7.59) 2.31 (0.20 – 25.98)
Lymphoma 5/3 1.78 (0.42 – 7.49) 4.34 (0.48 – 39.41)
Digestive tract 43/30 1.56 (0.97 – 2.51) 1.58 (0.95 – 2.64)
Digestive
system
59/39 1.67 (1.10 – 2.53) 1.79 (1.14 – 2.79)
Urinary system 4/8 0.53 (0.16 – 1.77) 0.79 (0.22 – 2.88)
Hematological
system
6/6 1.07 (0.34 – 3.32) 1.80 (0.42 – 7.65)
Gynecology 9/5 1.93 (0.64 – 5.79) 3.34 (0.89 – 12.53)
≥ 2 histories# 5/11 0.48 (0.17 – 1.39) 0.76 (0.24 – 2.47)
All sites# 106/70 1.71 (1.25 – 2.36) 2.13 (1.49 – 3.04)
*Adjusted for age, age at menarche, childbearing, menopause status; #family
history of breast cancer was excluded; bold data reflected P < 0.05.
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0.05 was applied in all tests.
Results
A total of 823 women with breast cancer and 823 age-
matched controls were studied. Age distribution of all par-
ticipants was shown in Table 1. The proportions of sub-
jects in each age group were almost the same (P > 0.05).
Cases and controls in this study were very well matched
on age. The other basic characteristics of all included sub-
jects were described previously [25].
The number of cases and controls with a history of se-
lected cancers was shown in Table 2. 106 subjects were
reported with a family history of selected cancers in case
group and 70 subjects in control group. Of these sub-
jects, more than 50% were reported with a family history
of digestive system cancer in both groups.
In univariate analysis (Table 2), a significant increase
in breast cancer was only observed in subjects with a family
history of esophagus cancer (OR: 2.79, 95% CI: 1.16 – 6.71),
digestive system cancer (OR: 1.67, 95% CI: 1.10 – 2.53), and
any other cancer (OR: 1.71, 95% CI: 1.25 – 2.36).
When age, age at menarche, childbearing, and meno-
pause status were adjusted (Table 2), a significant increase
in breast cancer was still observed in subjects with a family
history of esophagus cancer (OR: 2.70, 95% CI: 1.11 – 6.57),
digestive system cancer (OR: 1.79, 95% CI: 1.14 – 2.79)
and any other cancer (OR: 2.13, 95% CI: 1.49 – 3.04).
Additionally, a significantly increased breast cancer risk
was observed with a family history of lung cancer (OR:
2.49 95% CI: 1.10 – 5.65). No significant increase in breast
cancer was observed with a family history of cancer in
other systems (all P > 0.05). Furthermore, no significantly
increased breast cancer risk was observed in subjects with
two or more family histories of other cancers (OR: 0.76,
95% CI: 0.24 – 2.47).
In subgroup analysis (Table 3), a significant increase
in both hormone receptor positive (OR: 2.36, 95% CI:Table 1 Age distribution of participants in the case-control
study
Age groups Cases, n (%) Controls, n (%)
≤ 30 y 17 (2.1%) 17 (2.1%)
31 – 40 y 140 (17.0%) 140 (17.0%)
41 – 50 y 296 (36.0%) 298 (36.2%)
51 – 60 y 235 (28.6%) 233 (28.3%)
61 – 70 y 96 (11.7%) 93 (11.3%)
71 – 80 y 36 (4.4%) 39 (4.7%)
≥ 81 y 3 (0.4%) 3 (0.4%)
Total 823 (100%) 823 (100%)
Median 49 y 49 y
SD 10.82 y 10.82 y1.60 – 3.47) and negative (OR: 2.29, 95% CI: 1.38 – 3.78)
breast cancer was observed with a family history of any
other cancer. Importantly, a significant increase in hor-
mone receptor positive breast cancer was observed with a
family history of lung cancer (OR: 3.37, 95% CI: 1.45 –
7.82); however, subjects with a family history of lung can-
cer did not show a significant increase in hormone recep-
tor negative breast cancer (OR: 1.30, 95% CI: 0.33 – 5.14).
Additionally, a significant increase in hormone receptor
negative breast cancer was observed in subjects with a
family history of esophagus cancer (OR: 6.19, 95% CI:
2.30 – 16.71) and uterus cancer (including endometrial
and cervical cancers, OR: 6.92, 95% CI: 1.12 – 42.89),
and no significant increase in hormone positive breast
cancer was observed. Similarly, a significant increase in
hormone receptor negative breast cancer was observed
with a family history of digestive tract cancer (OR: 2.05,
95% CI: 1.03 – 4.10) and gynecology cancer (OR: 6.79,
95% CI: 1.46 – 31.65), and no significant increase in hor-
mone positive breast cancer was observed. Additionally, a
Table 3 Subgroup analysis of breast cancer risk according to family history of selected cancers
Site HR positive* HR negative* ≤ 50 y* > 50 y*
Cases/control (n/n) OR (95% CI) Cases/control (n/n) OR (95% CI) Cases/control (n/n) OR (95% CI) Cases/control (n/n) OR (95% CI)
breast 12/16 1.69 (0.69 – 4.17) 9/16 3.59 (1.36 – 9.47) 12/16 2.23 (0.81 – 6.14) 14/16 2.43 (0.73 – 8.20)
Lung 17/13 3.37 (1.45 – 7.82) 4/13 1.30 (0.33 – 5.14) 11/13 2.01 (0.70 – 5.79) 10/13 3.24 (0.85 – 12.42)
Esophagus 7/7 1.56 (0.53 – 4.55) 11/7 6.19 (2.30 – 16.71) 10/7 2.64 (0.81 – 8.66) 8/7 2.50 (0.65 – 9.67)
Stomach 15/17 1.69 (0.80 – 3.60) 4/17 0.65 (0.18 – 2.39) 8/17 1.10 (0.40 – 3.03) 11/17 1.49 (0.51 – 4.32)
Intestine 6/8 1.21 (0.37 – 3.95) 1/8 0.55 (0.06 – 4.68) 4/8 0.72 (0.15 – 3.36) 3/8 1.16 (0.22 – 6.11)
Liver 6/5 2.29 (0.68 – 7.70) 4/5 2.95 (0.74 – 11.84) 4/5 1.66 (0.37 – 7.53) 6/5 2.82 (0.55 – 14.58)
Pancreas 4/5 1.53 (0.40 – 5.84) 2/5 1.57 (0.28 – 8.66) 4/5 5.07 (0.56 – 45.84) 2/5 0.51 (0.09 – 2.91)
Gallbladder 1/2 2.14 (0.13 – 35.41) / / / / / /
Larynx 4/2 5.19 (0.53 – 50.70) / / / / 2/2 1.83 (0.16 – 20.55)
Bladder 1/5 0.41 (0.05 – 3.71) / / 1/5 0.39 (0.04 – 3.81) / /
Kidney 2/1 3.12 (0.28 – 35.11) / / 2/1 1.93 (0.17 – 21.76) / /
Prostate 1/2 2.78 (0.17 – 46.34) / / / / / /
Uterus 4/3 3.23 (0.58 – 17.98) 3/3 6.92 (1.12 – 42.89) 2/3 1.11 (0.15 – 8.11) / /
Appendix 1/2 1.83 (0.11 – 30.22) 1/2 6.01 (0.36 – 101.25) / / 1/2 0.99 (0.06 – 16.34)
Lymphoma 4/3 5.26 (0.54 – 51.20) 1/3 4.64 (0.28 – 78.24) 2/3 1.37 (0.09 – 22.14) / /
Digestive tract 27/30 1.57 (0.89 – 2.77) 16/30 2.05 (1.03 – 4.10) 22/30 1.49 (0.74 – 3.00) 21/30 1.63 (0.77 – 3.49)
Digestive system 37/39 1.79 (1.09 – 2.93) 22/39 2.29 (1.26 – 4.17) 31/39 1.88 (1.03 – 3.43) 28/39 1.67 (0.86 – 3.25)
Urinary system 4/8 1.19 (0.33 – 4.31) / / 4/8 1.12 (0.27 – 4.58) / /
Hematological system 4/6 1.78 (0.35 – 8.94) 2/6 3.02 (0.48 – 18.88) 3/6 0.75 (0.12 – 4.64) / /
Gynecology 5/5 2.78 (0.65 – 11.87) 4/5 6.79 (1.46 – 31.65) 3/5 1.74 (0.28 – 10.66) 6/5 6.16 (0.73 – 52.15)
Two or more histories# 4/11 0.96 (0.27 – 3.39) 1/11 0.58 (0.07 – 4.92) / / 5/11 1.54 (0.35 – 6.65)
All sites# 73/70 2.36 (1.60 – 3.47) 32/70 2.29 (1.38 – 3.78) 58/70 1.92 (1.21 – 3.05) 48/70 2.39 (1.36 – 4.20)
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(OR: 1.79, 95% CI: 1.09 – 2.93) and negative (OR: 2.29,
95% CI: 1.26 – 4.17) breast cancer was observed with a
family history of digestive system cancer.
Importantly, a significantly increased breast cancer risk
was observed with a family history of any other cancer
for women both younger (OR: 1.92, 95% CI: 1.21 – 3.05)
and older (OR: 2.39, 95% CI: 1.36 – 4.20) than 50 y
(Table 3). There was no significantly increased breast
cancer risk with a family history of any single cancer
for subjects older than 50 y or 50 y and younger. Interest-
ingly, a significant increase in breast cancer was observed
with a family history of digestive system cancer for sub-
jects 50 y and younger (OR: 1.88, 95% CI: 1.03 – 3.43) not
for subjects 50 y older (OR: 1.67, 95% CI: 0.86 – 3.25)
(Table 3).
Discussion
In this hospital-based case-control study, the risk of
breast cancer was increased in subjects with a family his-
tory of esophagus cancer, lung cancer and digestive sys-
tem cancer in first-degree relatives. In subgroup analysis,
the risk of hormone receptor positive breast cancer was
increased in subjects with a family history of lung can-
cer, while the risk of hormone receptor negative breast
cancer was increased in subjects with a family history of
esophagus cancer, uterus cancer, and gynecology cancer.
Additionally, a significant increase in breast cancer was
observed with a family history of digestive system cancer
for subjects 50 y and younger, not for subjects 50 y older.
Previous studies have reported that family history of
colon, prostate, ovarian cancers has been associated with
an increased breast cancer risk [9,19]. However, Negri E
and colleagues [8] have found that there was no material
association with family history of cancer in general, ex-
cluding breast cancer. Another previous study [27] have
found association between breast and prostate cancers.
In this study, we firstly found that breast cancer risk was
increased in subjects with a family history of lung cancer
and esophagus cancer. Importantly, the risk of breast
cancer was also increased in subjects with a family his-
tory of digestive system cancer in this study. Turati F
and colleagues [28] found a significant association be-
tween breast cancer and family history of colorectal can-
cer with a OR of 1.5. Lifestyle change and no healthy
lifestyles may contribute to increasing digestive system
cancer morbidity in developing countries. Breast cancer
and digestive system cancer may share some etiological
factors, including increased body mass index, low fruit
and vegetable intake, smoking, and low energy intake
[29-31]. Our findings and previous studies suggest that
healthy lifestyles, including high dietary fiber, increased
physical activity, and no smoking, should be kept[32]. Negri E and colleagues [8] have reported that
an unexpected relation of breast cancer risk with family
history of gallbladder cancer, based on only 7 cases and 1
control. They have inferred that this association may be
due simply to chance, since the lower confidence limit
was around 1. Turati F and colleagues [28] found a signifi-
cant association between breast cancer and family history
of hemolymphopoietic cancers. In this study, no relation
of breast cancer risk with family history of gallbladder
cancer and lymphoma was observed. Our findings con-
firm the conclusion of the previous studies. However,
there was an unexpected relation of breast cancer risk
with family history of lung cancer and esophagus cancer,
and these associations could not be due simply to chance
in this study. Nutritional and diet factors may contribute
to these associations. Moreover, ethnicity may contribute
to the disparity of our results with the previous studies.
Future studies in our country should be taken to confirm
our results.
The relationships between having a family history of
breast cancer and risk of subtypes of breast cancer defined
by hormone receptor status are inconsistent [18,19,33],
and the relationship between having a family history of
other cancers and risk of subtype of breast cancer has not
been reported. An increased risk of hormone receptor
negative breast cancer was observed in subjects with a
family history of esophagus cancer, uterus cancer, digestive
tract cancer, and gynecological cancer; however, no signifi-
cantly increased risk of hormone receptor positive breast
cancer was observed in subjects with a family history of
above cancers. Our findings suggest that hormone re-
ceptor positive and negative breast cancers have differ-
ent genetic components. The presence of mutations in
the BRCA1 gene are associated with hormone receptor
negative breast cancer [34]. Importantly, BRCA1/2 genes
mutations have been detected in gynecological cancer and
digestive system cancer [35-40]. BRCA1/2 genes muta-
tions may be contributed to the relationship between hav-
ing a family history of gynecological cancer and digestive
system cancer and increased risk of hormone receptor
negative breast cancer. Besides, other gene mutations may
also be contributed to the relationship, and should be de-
tected in future studies.
Jiang and colleagues find that women with a family
history of breast cancer were more likely to have hormone
receptor negative breast cancer than women without a
family history, and the association was limited to cancers
diagnosed before age 50 [33]. Similarly, we found a signifi-
cant increase in breast cancer was observed with a family
history of digestive system cancer for subjects 50 y and
younger not for subjects 50 y older. Prior estimates have
suggested more parts of women diagnosed with breast
cancer before age 50 years carry germ-line mutations in
BRCA1 than women after age 50 years [41]. The difference
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mutations.
Our study was the systematic investigation of all other
cancers in first-degree relatives and the subsequent
breast cancer risk. The strengths of this study are de-
scribed as following. First, previous studies suggest that
the recall of cancer in second-degree is less reliable
[8,42]. Only first-degree relatives were included in our
study to reduce recall bias. Second, cases of breast can-
cer may tend to recall a family history of other cancers
more accurately than controls [8], and the interviews of
family history for all cases and controls were performed
before diagnose by trained interviewers. Third, the path-
ology of all cases and controls was confirmed by an ex-
perienced pathologist. Benign breast disease was selected
as controls, which included fibroadenoma, mastopathy,
intraductal papilloma, and others. The association be-
tween breast cancer risk and family history of other can-
cers may be underestimated; however, no major recall
bias existed in the present case-control study.
However, several potential limitations of this study
should be considered when interpreting these results.
First, the information on other potential risk factors of
breast cancer such as diet, smoking, body mass index,
and number of siblings, was unavailable. Some of the
significant associations could be attributed to chance.
Moreover, number of first degree relatives [43] was not
adjusted in this study due to small number of cases ≥ 2
first degree relatives (Table 2). Second, age at diagnosis
of the affected relatives was not collected, so the rela-
tionship between breast cancer risk and age at diagnosis
of the affected relatives could not be calculated. Third,
due to the nature of the design of this study, our find-
ings should be confirmed by future cohort studies that
also considering other risk factors for breast cancer.
Forth, the number of incident cases from some neoplasms
was relatively small, and this limited the precision of the
risks estimates, especially for subgroup analyses. Some as-
sociations, which may be by chance findings or others
based on a limited number of exposed cases and controls,
need independent confirmation.
Conclusions
In conclusion, a family history of esophagus cancer, lung
cancer, and digestive system cancer in first-degree rela-
tives was directly associated with breast cancer risk. In
subgroup analysis, the influence of having a family his-
tory of other cancers seems more likely to be limited to
hormone receptor negative breast cancer. An increased
breast cancer risk was observed in subjects 50 y and
younger with a family history of digestive system cancer
in first-degree relatives. Future cohort studies with a lar-
ger sample are still needed to confirm our findings and
consider other risk factors.Abbreviations
CI: Confidence interval; ER: Estrogen receptor; OR: Odds ratio;
PR: Progesterone receptor; SD: Standard deviation.
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